Insmed Incorporated (INSM) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Bridgewater, NJ, United States. El CEO actual es William H. Lewis.
INSM tiene fecha de IPO 2000-06-01, 1,271 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $33.07B.
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company's commercial product, ARIKAYCE, is an inhaled antibiotic combination therapy approved for treating Mycobacterium avium complex lung disease in adults. Insmed's pipeline includes Brensocatib, an oral inhibitor of dipeptidyl peptidase 1 being developed for bronchiectasis and neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treatment candidate for pulmonary arterial hypertension and other rare pulmonary disorders. Founded in 1988 and headquartered in Bridgewater, New Jersey, the company specializes in addressing unmet medical needs in rare respiratory and systemic diseases.
